The FDA issued updated guidance on how healthcare professionals should dispense insulin pens: they should only go to a single patient in the original sealed carton.
The American Association of Clinical Endocrinologists released a new algorithm for the management of dyslipidemia and prevention of cardiovascular disease. (Endocrine Practice)
The Endocrine Society praised the European Commission’s new “Chemical Strategy for Sustainability” aimed at curbing the public’s exposure to endocrine-disrupting chemicals. “We now need further details and concrete actions to protect public health and minimize consumers’ exposure to these hazardous chemicals,” said Barbara Demeneix, PhD, DSc, chair of the society’s Endocrine-Disrupting Chemicals Advisory Group, in a statement.
Long-term follow-up data found teprotumumab (Tepezza) — approved in January — achieved a sustained response up to a year after the completion of treatment for thyroid eye disease, Horizon Therapeutics announced.
One more benefit of bariatric surgery: a significantly reduced risk for pancreatic cancer in those with comorbid obesity and diabetes. (U.S. News & World Report)
Could daily high-dose vitamin D really help prevent type 2 diabetes? (Diabetes Care)
The saga of the NDMA metformin recalls continues as Indian-based Marksans Pharma Limited expanded its voluntary recall to include an additional 76 unexpired lots of metformin hydrochloride extended-release tablets.
Amolyt Pharma announced its first participant was dosed in the phase I clinical trial for AZP-3601 — an investigative parathyroid hormone analog for the treatment of hypoparathyroidism.